Form 4: Atara Biotherapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4
Amar Murugan, EVP and Chief Legal Officer of Atara Biotherapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Amar Murugan, the EVP and Chief Legal Officer of Atara Biotherapeutics, sold 32,401 shares of common stock on May 16, 2024, at a price of $0.617 per share.
- The sale was executed to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units.
- Following the transaction, Murugan directly owns 695,120 shares of Atara Biotherapeutics.
- The sale price represents the weighted average price of all shares sold by a broker on May 16 and May 17, 2024, on behalf of a group of employees to satisfy their withholding tax liabilities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of the stock sale transaction. |
| 05/16/2024 | Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units. |
| 05/17/2024 | Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units. |
| 05/20/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.